Navigation Links
Axelar's Board Strengthened
Date:4/27/2010

STOCKHOLM, April 27, 2010 /PRNewswire/ -- Axelar AB, a Karolinska Development portfolio company, today announces that Goran Pettersson has been elected new chairman of the board and Ingemar Kihlstrom board member. Both have vast international experience from leading positions in the pharmaceutical industry.

"We have just secured 25 MSEK financing for the continued development of Axelar's anticancer compound "AXL1717". It's encouraging that we at the same time are able to further strengthen the board with Goran and Ingemar, both having so much international experience from the pharmaceutical industry. They will contribute with valuable knowledge in the continued development of Axelar," says Johan Harmenberg, CEO Axelar AB.

Goran Pettersson has held leading positions in Astra, KabiVitrum, Pharmacia/PharmaciaUpJohn and Meda. Currently, he is also chairman of the board in Medivir AB, OxyPharma AB and Vivoxid Oy, and board member in Diamyd Medical AB, Pfizer Sweden Pensionsstiftelse and Recipharm AB.

Ingemar Kihlstrom has held leading positions in Pharmacia, Aros Securities and ABG Sundal Collier. He is currently serving as board member in a number of Scandinavian companies including being chairman of the board in Artimplant AB, Creative Antibiotics AB, Hammercap AB and RecoPharma AB, and vice chairman of the board in Diagenic ASA.

TO THE EDITORS

About Axelar

Axelar is a Swedish biotech company founded in 2003. The company is developing an insulin-like growth factor-1 (IGF-1) receptor inhibitor for cancer treatment. Axelar is part of the Karolinska Development portfolio. http://www.axelar.se

About AXL1717

Axelar's lead compound, AXL1717, provides a novel treatment for a wide range of cancers. AXL1717 is the first targeted oral small-molecule IGF-1 receptor inhibitor with no effect on the insulin receptor. AXL1717 is presently undergoing Phase I/II clinical trials and the compound combines a superior preclinical efficacy against numerous tumors with an excellent tolerability profile. Most tumor cells are dependent on the IGF-1 receptor signal pathway and the IGF-1 receptor is therefore regarded as an excellent target for cancer therapy. To date, there are no IGF-1 receptor inhibitor drugs on the market.

About Karolinska Development

Karolinska Development manages one of the largest portfolios of life science companies in Europe. Using a unique, highly cost efficient business model, the management team guides the commercialization of world class life science innovations, helping to shape the next generation Pharma industry. Since 2003, Karolinska Development has built a portfolio of some 40 companies; among the company's projects 12 compounds are undergoing clinical trials. The portfolio also includes a total of 21 potential first-in-class products. http://www.karolinskadevelopment.com

    For further information, please contact:
    Johan Harmenberg, CEO, Axelar AB
    Phone: +46(0)705-14-54-53, e-mail: johan.harmenberg@axelar.se



'/>"/>
SOURCE Karolinska Development and Axelar
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Nobel Prize Awarded to Foundation for Biomedical Research Board Member
2. Seal Shield Launches Worlds First Antibacterial, Dishwasher Safe Keyboard and Mouse for Infection Control
3. American Board of Internal Medicine President Named to Alzheimers Study Group
4. GeoVax Labs, Inc. Selects Financial Relations Board as Investor Relations Counsel
5. Berkery Noyes Represented The Thomson Corporation in the Sale of CenterWatch and New England Institutional Review Board to Jobson Medical Information
6. William R. Ringo Joins Hyperion Therapeutics, Inc. Board of Directors as Chairman
7. Independent Data Safety Monitoring Board Recommends Continuation of Sangarts Pivotal Phase III Trials of Hemospan(R) Following Second Interim Review
8. UBC Forms European Advisory Board to Enhance Data Quality of CNS Trials
9. ASPIRE Independent Review Board Announces 10 Ways to Protect Participants Rights in Clinical Drug Trials and Optimize Results From Research
10. Silence Therapeutics Announces Board Changes
11. Velcura Therapeutics, Inc. Adds William Brinkerhoff to its Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... , June 23, 2016 ... CAPR ), a biotechnology company focused on the ... announced that patient enrollment in its ongoing randomized ... has exceeded 50% of its 24-patient target. Capricor ... the third quarter of 2016, and to report ...
(Date:6/23/2016)... BOGOTA, Colombia , June 23, 2016  Astellas today announced the establishment of Astellas Farma Colombia (AFC), a ... second affiliate in Latin America . ... ... ... ...
(Date:6/23/2016)... , June 23, 2016  Experian ... integrating and transforming the patient payment and ... several innovative new products and services that ... its revenue cycle offerings. These award-winning solutions ... efficient workflows, remain compliant in an ever-changing ...
Breaking Medicine Technology:
(Date:6/24/2016)... , ... June 24, 2016 , ... People across the ... Genome magazine’s Code Talker Award, an essay contest in which patients and their families ... to be presented at the 2016 National Society of Genetic Counselors (NSGC) Annual Education ...
(Date:6/24/2016)... ... June 24, 2016 , ... Puradigm® & ... (TGIG), has initiated cultivation and processing operations at its production facility, and opened ... , Puradigm is the manufacturer of a complete system of proactive air and ...
(Date:6/24/2016)... ... June 24, 2016 , ... Venture Construction Group (VCG) sponsors ... on June 20th at the Woodmont Country Club at 1201 Rockville Pike, Rockville, Maryland, ... to helping service members that have been wounded in battle and their families. Venture ...
(Date:6/24/2016)... ... June 24, 2016 , ... Finally, a bruise cream that ... dermaka cream can be incorporated into the post-surgical treatment plans of a variety of ... , dermaka cream is very effective for bruising and causes a rapid resolution of ...
(Date:6/24/2016)... New York (PRWEB) , ... June 24, 2016 , ... ... marijuana patients optimize the ingestion of their medication by matching users with high quality ... users to compare pieces with no commitment. , Inhale was founded by two brothers, ...
Breaking Medicine News(10 mins):